ANALYSIS OF THE COST PER RESPONDER OF BIOLOGICAL TREATMENTS FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

被引：0
|
作者：
Kanevsky, D. [1 ]
Rodriguez, M. F. [1 ]
Suarez Ordonez, S. [1 ]
Elgart, J. [2 ]
Mazzuoccolo, L. D. [3 ]
机构：
[1] Abbvie, Buenos Aires, DF, Argentina
[2] UNLP, CONICET, CENEXA, Ctr Endocrinol Expt & Aplicada, La Plata, Buenos Aires, Argentina
[3] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU23
引用
收藏
页码：S607 / S607
页数：1
相关论文
共 50 条
  • [41] Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis*
    Teeple, Amanda
    Fitzgerald, Timothy
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 518 - 524
  • [42] COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
    Suzuki, C.
    Lopes, N.
    Gilloteau, I
    Graham, C.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [43] Cost-per-Responder Analysis of Infliximab Compared to Adalimumab Among Individuals with Moderate to Severe Ulcerative Colitis
    Lofland, J.
    Gunnarsson, C.
    Mallow, P.
    Rizzo, J.
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S418 - S418
  • [44] A COST-PER-RESPONDER ANALYSIS OF SECUKINUMAB COMPARED WITH USTEKINUMAB THROUGH 52 WEEKS IN GERMANY: RESULTS FROM THE CLEAR STUDY OF PATIENTS WITH MODERATE TO SEVERE PSORIASIS
    Augustin, M.
    Graham, C. N.
    Miles, L.
    Gilloteau, I
    O'Neill, C. B.
    Neidhardt, K.
    McBride, D.
    VALUE IN HEALTH, 2017, 20 (05) : A158 - A158
  • [45] Cost-per-responder analysis of guselkumab versus ixekizumab with the use of efficacy results from pivotal clinical trials in patients with moderate to severe plaque psoriasis
    Teeple, Amanda
    Muser, Erik
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB88 - AB88
  • [46] COST PER ADDITIONAL RESPONDER ASSOCIATED WITH BIOLOGIC USE IN PSORIASIS
    Foster, S.
    Zhu, B.
    Al Sawah, S.
    VALUE IN HEALTH, 2015, 18 (03) : A297 - A297
  • [47] COST PER RESPONDER ANALYSIS OF CALCIPOTRIOL PLUS BETAMETHASONE DIPROPIONATE AEROSOL FOAM VERSUS NON-BIOLOGIC SYSTEMIC THERAPY IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
    Becla, L.
    Carrascosa, J. M.
    Antunes, J. F.
    Bewley, A. P.
    Delgado Perala, M.
    Charrua, M. F.
    O'shaughnessy, S.
    Treloggen, J. R.
    Sawyer, L. M.
    Cornic, L.
    VALUE IN HEALTH, 2018, 21 : S425 - S425
  • [48] Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis
    Messori A.
    Trippoli S.
    Fadda V.
    Maratea D.
    Marinai C.
    Drugs - Real World Outcomes, 2015, 2 (1) : 23 - 27
  • [49] Relative efficacy and costs per responder for adalimumab versus secuki-numab in the treatment of moderate to severe psoriasis
    Armstrong, April
    Betts, Keith
    Sundaram, Murali
    Li, Junlong
    Wu, Eric
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB267 - AB267
  • [50] Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
    Caporali, Roberto
    Ravasio, Roberto
    Raimondo, Paola
    Salaffi, Fausto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 69 - 79
12345